MediciNova, Inc.
MNOV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.49 | -0.34 | -3.59 | 6.66 |
| FCF Yield | -2.74% | -3.59% | -5.28% | -1.88% |
| EV / EBITDA | -9.98 | -8.41 | -11.07 | -19.77 |
| Quality | ||||
| ROIC | -7.61% | -7.62% | -6.34% | -5.99% |
| Gross Margin | -31.59% | 13.56% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.56 | 0.70 | 1.32 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.35% | 512,384.35% | -100.00% | -100.00% |
| Free Cash Flow Growth | 26.03% | 39.04% | -95.87% | 4.94% |
| Safety | ||||
| Net Debt / EBITDA | 10.76 | 9.43 | 11.33 | 12.64 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -413.72 | -350.49 | 0.00 | -19,166.40 |